PAIN
Volume 149, Issue 2 , Pages 316-324 , May 2010

Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin

Received 7 September 2009 ,Revised 20 January 2010 ,Accepted 16 February 2010.

References 

  1. Andrews PV, Helme RD, Thomas KL. NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. Br J Pharmacol. 1989;97:1232–1238
  2. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248:3–10
  3. Averbeck B, Reeh PW. Interactions of inflammatory mediators stimulating release of calcitonin gene-related peptide, substance P and prostaglandin E2 from isolated rat skin. Neuropharmacology. 2001;40:416–423
  4. Bach-Rojecky L, Lackovic Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005;46:201–208
  5. Bach-Rojecky L, Dominis M, Lacković Z. Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam Clin Pharmacol. 2008;22:503–509
  6. Baraniuk JN, Kowalski ML, Kaliner MA. Relationship between permeable vessels, nerves and mast cells in rat cutaneous neurogenic inflammation. J Appl Physiol. 1990;68:2305–2311
  7. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre L. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313:54–56
  8. Brain SD, Newbold P, Kajekar R. Modulation of the release and activity of neuropeptides in the microcirculation. Can J Physiol Pharmacol. 1995;73:995–998
  9. Carmichael NM, Charlton MP, Dostrovsky JO. Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. Pain. 2008;134:97–105
  10. Carmichael NM, Dostrovsky JO, Charlton MP. Enhanced vascular permeability in rat skin induced by sensory nerve stimulation: evaluation of the time course and appropriate stimulation parameters. Neuroscience. 2008;153:832–841
  11. Chaddock JA, Purkiss JR, Alexander FC, Doward S, Fooks SJ, Friis LM, et al. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord. 2004;19:S42–S47
  12. Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol. 2006;24:155–460
  13. Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol. 2009;160:721–722
  14. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain. 2004;107:125–133
  15. Cull-Candy SG, Lundh H, Thesleff SJ. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol. 1976;260:177–203
  16. Davarian S, Kalantari KK, Rezasoltani A, Rahimi A. Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol. 2008;49:75–79
  17. de Paiva A, Poulain B, Lawrence GW, Shone CC, Tauc L, Dolly JO. A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem. 1993;268:20838–20844
  18. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the receptor for botulinum neurotoxin type A. Science. 2006;312:592
  19. Dressler D, Saberi FA, Barbosa EF. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63:180–185
  20. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–43
  21. Gamse R, Saria A. Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide. Eur J Pharmacol. 1985;7:61–66
  22. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:315–325
  23. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–69
  24. Gonzalez HL, Carmichael N, Dostrovsky JO, Charlton MP. Evaluation of the time course of plasma extravasation in the skin by digital image analysis. J Pain. 2005;6:681–688
  25. Kaufman JL, Karceski S. Using botulinum toxin to treat diabetic foot pain. Neurology. 2009;72:e82–e85
  26. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg. 2004;30:452–455
  27. Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003;250:188–193
  28. Lebeda FJ, Adler M, Erickson K, Chushak YJ. Onset dynamics of type A botulinum neurotoxin-induced paralysis. Pharmacokinet Pharmacodyn. 2008;35:251–267
  29. Lee JN, Jee SH, Chan CC, Lo W, Dong CY, Lin SJ. The effects of depilatory agents as penetration enhancers on human stratum corneum structures. J Invest Dermatol. 2008;128:2240–2247
  30. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol. 1979;310:175–183
  31. Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A. The nonpeptide tachykinin antagonist, CP 96–345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol. 1992;105:527–530
  32. Lin Q, Li D, Xu X, Zou X, Fang L. Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain. 2007;3:30
  33. Lowe N, Campanati A, Bodokh I, Cliff S, Jaen P, Kreyden O, et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol. 2004;151:1115–1122
  34. Lucioni A, Bales GT, Lotan TL, McGegee DS, Cook SP, Dapp DE. Botulinum toxin type A inhibits sensory neuropeptides release in rat baldder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–370
  35. Lynn B, Ye W, Cotsell B. The actions of capsaicin applied topically to the skin of the rat on C-fiber afferents, antidromic vasodilation and substance P levels. Br J Pharmacol. 1992;107:400–406
  36. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006;580:2011–2014
  37. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864–2874
  38. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–4992
  39. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5:274–279
  40. Pacini S, Gulisano M, Punzi T, Ruggiero M. Transdermal delivery of Clostridium botulinum toxin type A by pulsed current iontophoresis. J Am Acad Dermatol. 2007;57:1097–1099
  41. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–1268
  42. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000;59:1403–1406
  43. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–283
  44. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006;175:1138–1142
  45. Sakaba T, Stein A, Jahn R, Neher E. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Science. 2005;309:491–494
  46. Sheean G. Botulinum toxin for the treatment of musculosketetal pain and spasm. Curr Pain Headache Resp. 2002;6:460–469
  47. Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, et al. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol. 1999;163:2410–2415
  48. Szolcsanyi J. Antidromic vasodilation and neurogenic inflammation. Agents Actions. 1988;23:4–11
  49. Towler PK, Brain SD. Activity of tachykinin NK1and bradykinin B2 receptor antagonists, and an opioid ligand at different stimulation parameters in neurogenic inflammation in the rat. Neurosci Lett. 1998;257:5–8
  50. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain. 2007;130:76–83
  51. Verderio C, Grumelli C, Raiteri L, Coco S, Paluzzi S, Caccin P, et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic. 2007;8:142–153
  52. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61:940–944
  53. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–258
  54. Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007;19:84–87
  55. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473–1478

PII: S0304-3959(10)00116-8

doi: 10.1016/j.pain.2010.02.024

PAIN
Volume 149, Issue 2 , Pages 316-324 , May 2010

Article Tools

* Image Usage & Resolution